ino-4212

Vaccineexperimental

Clinical trial activity

1 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2015 (NCT02464670)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • EbolavirusImmunity, active

    Ebolavirus immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ino-4212

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02464670Phase 1May 1, 2015Defense Advanced Research Projects Agency, GeneOne Life Science, Inovio Pharmaceuticals
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Defense Advanced Research Projects AgencyGovernment1012015
GeneOne Life ScienceFor profit1012015
Inovio PharmaceuticalsFor profit1112015
3 organizations
Page 1 / 1